Skip to main content
Fig. 2 | BMC Ophthalmology

Fig. 2

From: Aggravation of retinal hard exudates after intravitreal anti-vascular endothelial growth factor therapy for cystoid macular edema and the risk factors: a retrospective study

Fig. 2

Hard exudates severity at baseline, month 1 and month 3. The figure shows the percentage of eyes in each category in both (A) DR and (B) BRVO groups. Hard exudate severity categories were defined according to Early Treatment Diabetic Retinopathy Study criteria as absent (no hard exudate present), minimal (> 0–0.1 mm2), mild (> 0.1–0.5 mm2), moderate (> 0.5–2.5 mm2), and severe (> 2.5 mm2)

Back to article page

BMC Ophthalmology

ISSN: 1471-2415

Contact us